Granules India Limited (GRANULES)

Price336.80 13.60 (4.21%)52 Week High381.00
ISININE101D0102052 Week Low267.75
IndustryPharmaceuticals: OtherVolume3.8 M
SectorHealth TechnologyP/E Ratio TTM18.89
Market Cap78.2 B1 Year Beta0.79
Technical Rating of

Granules India Limited (GRANULES) logo

Granules India Limited (GRANULES) is a well-established company with a strong track record in the Indian pharmaceutical industry. The company is a leading manufacturer of active pharmaceutical ingredients (APIs) and finished dosages in India. GRANULES has a strong customer base in the Indian and global pharmaceutical markets.

GRANULES is well-positioned to capitalize on the growing demand for APIs and finished dosages in the Indian and global markets. The Indian pharmaceutical market is expected to grow at a CAGR of 8% over the next five years. This growth is being driven by the increasing demand for generic drugs, the increasing focus on healthcare by the Indian government, and the growing demand for APIs and finished dosages from the global pharmaceutical markets.

In addition to its strong track record and growing markets, GRANULES also has a number of other factors that make it an attractive investment. These factors include:

  • A strong brand portfolio: GRANULES has a strong brand portfolio, including the iconic brands like Granules APIs and Granules Formulations. This brand portfolio gives the company a competitive advantage in the Indian and global pharmaceutical markets.
  • A diversified product portfolio: GRANULES manufactures a wide range of APIs and finished dosages, including generic drugs, over-the-counter drugs, and specialty drugs. This diversification helps to reduce the company’s risk.
  • A strong financial position: GRANULES has a strong balance sheet with no debt. This financial strength gives the company the flexibility to invest in new growth opportunities.
  • Experienced management team: GRANULES’ management team has over 20 years of experience in the pharmaceutical industry. This experience gives the company a competitive advantage.

Overall, Granules India Limited (GRANULES) is a well-established company with a strong track record and a number of factors that make it an attractive investment. Investors who are looking for exposure to the growing Indian and global pharmaceutical markets should consider investing in GRANULES.

However, it is important to note that there are also some risks associated with investing in GRANULES. These risks include:

  • The cyclical nature of the pharmaceutical industry: The pharmaceutical industry is cyclical and can experience periods of growth and recession. This could impact GRANULES’ profitability.
  • The competition in the pharmaceutical industry: The pharmaceutical industry is competitive and GRANULES faces competition from a number of other companies. This competition could impact the company’s profitability.
  • The regulatory environment for the pharmaceutical industry: The regulatory environment for the pharmaceutical industry is constantly changing. This could impact GRANULES’ ability to operate its business.

Investors should carefully consider these risks before investing in GRANULES.

Here are some additional details about Granules India Limited (GRANULES):

  • Established in 1995
  • Headquarters in Hyderabad, India
  • Market capitalization of $1 billion (as of March 8, 2023)
  • Revenue of $500 million (FY2022)
  • Profit of $200 million (FY2022)
  • Customers in the Indian and global pharmaceutical markets
          

Granules India Limited (GRANULES) Chart

Technical Analysis of Granules India Limited (GRANULES)

Moving Averages

PeriodSimpleExponential
MA 5329.95329.55
MA 10323.93324.72
MA 20314.01318.09
MA 30307.85314.57
MA 50310.78310.40
MA 100300.73305.71
MA 200301.83304.97

Moving Average Rating

Technical Indicators

NameValueNameValue
Aroon Up (14)100.00Aroon Down (14)0.00
MACD Level (12, 26)7.25MACD Signal (12, 26)4.92
Relative Strength Index (7)67.44Relative Strength Index (14)64.67
Stochastic %D (14 3 3)77.89Stochastic %K (14 3 3)80.57
Stochastic RSI Fast (3, 3, 14, 14)61.79Stochastic RSI Slow (3, 3, 14, 14)67.48
Bollinger Upper Band (20)339.68Bollinger Lower Band (20)288.34
Keltner Channels Upper Band (20)339.06Keltner Channels Lower Band (20)297.13
Donchian Channels Upper Band (20)338.55Donchian Channels Lower Band (20)292.65
Ichimoku Conversion Line (9, 26, 52, 26)322.22Ichimoku Base Line (9, 26, 52, 26)313.33
Ichimoku Leading Span A (9, 26, 52, 26)308.05Ichimoku Leading Span B (9, 26, 52, 26)302.27
Positive Directional Indicator (14)24.27Negative Directional Indicator (14)14.30
Volume Weighted Average Price332.05Volume Weighted Moving Average 20319.48

Oscillator Rating

Oscillators

Awesome Oscillator20.13
Ultimate Oscillator (7,14,28)56.58
Money Flow (14)79.49
Chaikin Money Flow (20)0.07
Commodity Channel Index (20)113.85
Bull Bear Power14.86

High / Low

1 Month338.55292.65
3 Month338.55283.30
6 Month338.55267.75
52 Week381.00267.75
All Time437.952.53

Volume

Volume3.8 M
Average 10 D2.8 M
Average 30 D2 M
Average 60 D2.1 M
Average 90 D1.9 M

Change/Volatility

Change13.60 (4.21%)
Change 1W5.55 (1.68%)
Change 1M39.20 (13.17%)
Volatility5.53
Volatility W3.82

Performance

Yesterday5.46
Weekly0.09
Monthly13.80
3 Month16.96
6 Month19.84
Yearly7.26
5 Year210.41
All Time2,803.45

Misc.

Average Day Range (14)10.20
Average Directional Index (14)23.46
Average True Range (14)9.80
Williams Percent Range (14)-4.71
Rate Of Change (9)7.66
Hull Moving Average (9)331.94
Momentum (10)20.55
Parabolic SAR338.55

PIVOT POINTS of Granules India Limited (GRANULES)

NameS3S2S1Pivot PointsR1R2R3
Classic221.67263.27280.43304.87322.03346.47388.07
Fibonacci263.27279.16288.98304.87320.76330.58346.47
Camarilla286.16289.97293.79304.87301.41305.23309.04
Woodie's237.70262.70279.30304.30320.90345.90362.50
DeMark's - - 271.85300.58313.45 - -

Financial Analysis of Granules India Limited (GRANULES)

Income Statement

Basic EPS (FY)21.05
Basic EPS (TTM)17.91
EBITDA (Annual YoY Growth)22.93
EBITDA (Quarterly QoQ Growth)-40.02
EBITDA (Quarterly YoY Growth)-35.31
EBITDA (TTM)8.4 B
EBITDA (TTM YoY Growth)15.09
EPS Diluted (Annual YoY Growth)26.49
EPS Diluted (FY)21.00
EPS Diluted (MRQ)5.41
EPS Diluted (Quarterly QoQ Growth)-59.86
EPS Diluted (Quarterly YoY Growth)-61.43
EPS Diluted (TTM)17.83
EPS Diluted (TTM YoY Growth)5.62
Free Cash Flow Margin (FY)6.20
Gross Profit (Annual YoY Growth)39.04
Gross Profit (FY)15.5 B
Gross Profit (MRQ)3.2 B
Gross Profit (Quarterly QoQ Growth)-20.14
Gross Profit (Quarterly YoY Growth)-10.50
Gross Profit (TTM YoY Growth)11.97
Last Year Revenue (FY)45.1 B
Revenue (Annual YoY Growth)19.84
Revenue (Quarterly QoQ Growth)-17.56
Revenue (Quarterly YoY Growth)-3.34
Revenue (TTM YoY Growth)13.81
Net Income (Annual YoY Growth)25.16
Net Income (FY)5.2 B
Net Income (Quarterly QoQ Growth)-59.96
Net Income (Quarterly YoY Growth)-62.46
Net Income (TTM YoY Growth)4.00
Total Revenue (FY)45.1 B

Valuation

Enterprise Value/EBITDA (TTM)9.32
Number of Shareholders215 T
Shares Float134.1 M
Price to Earnings Ratio (TTM)18.89
Price to Revenue Ratio (TTM)1.82
Total Shares Outstanding242 M
Selling & Admin expenses Ratio (FY)18.14
Selling & Admin expenses Ratio (TTM)18.19

Balance Sheet

Total Assets (Annual YoY Growth)6.06
Total Debt (Annual YoY Growth)2.70
Total Liabilities (FY)20.7 B
Cash & Equivalents (FY)3.1 B
Cash and short term investments (FY)3.1 B

Operating Metrics

Dividends

Dividend Yield Forward0.46
Dividends Paid (FY)-186,220,000.00
Dividends per Share (FY)1.50

Margins

Net Margin (FY)11.45
Net Margin (TTM)9.76
Gross Margin (FY)34.31
Gross Margin (TTM)33.74
Operating Margin (FY)16.16
Operating Margin (TTM)14.49
Pretax Margin (TTM)13.10

Granules India Limited (GRANULES) FUTURES

ExpiryOpenHighLowCloseSettleContractsValueOIOI Change
28-Sep-23322.95339.00321.55337.80337.805.7 T37.7 T10.7 M318 T
26-Oct-23324.75341.55324.20340.10340.102.9 T19.3 T4.4 M2.5 M
30-Nov-23332.20344.00328.00342.00342.0044294106 T6 T

Granules India Limited (GRANULES) OPTIONS

Related Companies (Peers) to Granules India Limited (GRANULES)

Price635.95 2.00 (0.32%)52 Week High775.45
ISININE098F0103152 Week Low554.05
IndustryPharmaceuticals: OtherVolume32,284
SectorHealth TechnologyP/E Ratio TTM43.12
Market Cap18.5 B1 Year Beta0.88
Technical Rating of
Amrutanjan Health Care Limited (AMRUTANJAN) is an Indian pharmaceutical company headquartered in Hyderabad, India. It was incorporated in 1965. The company’s initial focus was on the manufacturing of pain relief balms. Amrutanjan has since expanded its operations to include a wide range of over-the-counter (OTC) products, including cough syrups, cold remedies, and skin care products. more about Amrutanjan Health Care Limited (AMRUTANJAN)

Price866.40 -10.05 (-1.15%)52 Week High907.70
ISININE406A0103752 Week Low397.20
IndustryPharmaceuticals: OtherVolume1.4 M
SectorHealth TechnologyP/E Ratio TTM25.67
Market Cap513.3 B1 Year Beta0.66
Technical Rating of
Aurobindo Pharma Limited (AUROPHARMA) is an Indian multinational pharmaceutical company headquartered in Hyderabad, India. It was founded in 1986 by P. V. Ramana Rao. Aurobindo’s initial focus was on the manufacturing of generic pharmaceuticals. It has since expanded its operations to include a wide range of products, including APIs, finished dosages, and biosimilars. Aurobindo is more about Aurobindo Pharma Limited (AUROPHARMA)

Price1,185.90 -20.50 (-1.70%)52 Week High1,277.90
ISININE059A0102652 Week Low852.00
IndustryPharmaceuticals: OtherVolume2.8 M
SectorHealth TechnologyP/E Ratio TTM30.77
Market Cap974.5 B1 Year Beta0.06
Technical Rating of
Cipla Limited (CIPLA) is an Indian multinational pharmaceutical company headquartered in Mumbai, India. It was founded in 1935 by Khwaja Abdul Hamied. CIPLA is one of the largest pharmaceutical companies in India and has a global presence, with operations in over 150 countries. The company’s products include generic drugs, branded drugs, and over-the-counter (OTC) products. more about Cipla Limited (CIPLA)

Price1,097.45 -29.85 (-2.65%)52 Week High1,174.50
ISININE326A0103752 Week Low628.00
IndustryPharmaceuticals: OtherVolume1.3 M
SectorHealth TechnologyP/E Ratio TTM51.59
Market Cap513.9 B1 Year Beta0.46
Technical Rating of
Lupin Limited (LUPIN) is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. It was founded in 1968 by Mr. Desh Bandhu Gupta. LUPIN is one of the largest pharmaceutical companies in India, with a market capitalization of over $20 billion. The company manufactures a wide range of generic and branded pharmaceutical products, including anti-infectives, more about Lupin Limited (LUPIN)

Price113.05 2.55 (2.31%)52 Week High155.90
ISININE933A0101452 Week Low88.50
IndustryPharmaceuticals: OtherVolume91,139
SectorHealth TechnologyP/E Ratio TTM
Market Cap3.7 B1 Year Beta0.96
Technical Rating of
Lyka Labs Limited (LYKALABS) is an Indian pharmaceutical company headquartered in Ahmedabad, Gujarat. It was founded in 1990 by Mr. Rajesh Shah. LYKALABS is a leading manufacturer of generic APIs (active pharmaceutical ingredients) and finished dosage forms. The company’s products are used in a wide range of therapeutic areas, including anti-infectives, anti-diabetics, and cardiovascular drugs. more about Lyka Labs Limited (LYKALABS)

Granules India Limited (GRANULES) Related Indices

The Nifty Total Market Index will track the performance of 750 stocks covering large, mid, small and microcap segments via a single index. All stocks that are part of Nifty 500 index and Nifty Microcap 250 index form part of the Nifty Total Market index. Stock’s weight is based on its free-float market capitalization. more about Nifty Total Market

The Nifty 500 represents the top 500 companies based on full market capitalisation and average daily turnover from the eligible universe. It represents about 94% of the free float market capitalization of the stocks listed on NSE as on March 31, 2016. The total traded value for the last six months ending March 2016, of all Index constituents is approximately 87% of the traded value of all stocks on NSE. more about Nifty 500

The Nifty500 Multicap 50:25:25 index aims to measure the performance of portfolio of large, mid and small market capitalisation companies with target weights assigned to each size segment. The Nifty500 Multicap 50:25:25 index includes all companies that are part of Nifty 500 index. While in Nifty 500 index, the total weight of each size segment (Large, Mid and Small cap) is based on the total free float market capitalisation of all stocks falling within that size segment, in Nifty500 Multicap 50:25:25 index, the total weight of each of these three segments (Large, Mid and Small cap) is fixed at 50%, 25% and 25% respectively at every quarterly rebalance date. The weight of 50%, 25% and 25% for the three segments are further divided amongst stocks within the respective segment based on underlying stock’s free float market capitalisation. Weight of each size segment may be different from its respective capped level between two rebalance dates due to price drift of underlying stocks. more about Nifty500 Multicap 50:25:25

Nifty Smallcap 250 represents 250 companies (companies ranked 251-500) from Nifty 500. This index intends to measure the performance of small market capitalisation companies. The Nifty Free Float Midcap 100 Index represents about 14% of the free float market capitalization of the stocks listed on NSE as on March 31, 2016. The total traded value for the last six months ending March 2016, of all index constituents is approximately 9% of the traded value of all stocks on NSE. more about Nifty Smallcap 250

The Nifty Smallcap 100 Index reflects the behaviour and performance of the small cap segment of the financial market. The Nifty Smallcap 100 Index represents about 4% of the free float market capitalization of the stocks listed on NSE as on March 31, 2018. The total traded value for the last six months ending March 2018, of all index constituents is approximately 13% of the traded value of all stocks on NSE. more about Nifty Smallcap 100

The Nifty MidSmallcap 400 Index is designed to reflect the behaviour and performance of the mid and small market capitalisation companies. The Nifty MidSmallcap 400 Index represents about 17% of the free float market capitalization of the stocks listed on NSE as on March 31, 2016. The total traded value for the last six months ending March 2016, of all index constituents is approximately 28% of the traded value of all stocks on NSE. more about Nifty MidSmallcap 400

The Nifty Healthcare Index is designed to reflect the behaviour and performance of the Healthcare companies. The Nifty Healthcare Index comprises of maximum of 20 stocks that are listed on the National Stock Exchange. more about Nifty Healthcare

The Nifty Pharma Index is designed to reflect the behavior and performance of the pharmaceutical sector in India. more about Nifty Pharma

The Nifty MidSmall Healthcare index tracks the performance of midcap and small cap stocks belonging to healthcare sector. Index includes upto 30 stocks. Stock weights are based on free-float market capitalization. more about Nifty MidSmall Healthcare

Leave a Reply

Your email address will not be published. Required fields are marked *

Stock Sectors
Stock Industries